Tamoxifen for the prevention of breast cancer. Important questions remain unanswered, and existing trials should continue.
作者信息
Bruzzi P
出版信息
BMJ. 1998 Apr 18;316(7139):1181-2. doi: 10.1136/bmj.316.7139.1181.
Abstract
摘要
相似文献
1
Tamoxifen for the prevention of breast cancer. Important questions remain unanswered, and existing trials should continue.他莫昔芬用于预防乳腺癌。重要问题仍未得到解答，现有试验应继续进行。
BMJ. 1998 Apr 18;316(7139):1181-2. doi: 10.1136/bmj.316.7139.1181.
2
Tamoxifen for breast-cancer prevention.
Lancet. 2003 Jan 11;361(9352):177-8; author reply 178. doi: 10.1016/S0140-6736(03)12211-8.
3
Tamoxifen and the breast cancer prevention trial: women helping women.他莫昔芬与乳腺癌预防试验：女性互助。
J Womens Health. 1998 Apr;7(3):279-80. doi: 10.1089/jwh.1998.7.279.
4
Tamoxifen and breast cancer prevention: what should you tell your patients?他莫昔芬与乳腺癌预防：你该如何告知你的患者？
CMAJ. 1998 Jun 16;158(12):1615-7.
5
Re: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
J Natl Cancer Inst. 1999 Apr 21;91(8):730. doi: 10.1093/jnci/91.8.730.
6
Keeping breast cancer at bay. Women at risk are asked to weigh the pros and cons of a prevention pill.预防乳腺癌。有风险的女性被要求权衡一种预防药物的利弊。
US News World Rep. 1999 May 31;126(21):76.
7
Tamoxifen or raloxifene in postmenopausal women for prevention of breast cancer: a tale of two choices--counterpoint.绝经后女性使用他莫昔芬或雷洛昔芬预防乳腺癌：两种选择的对比——正方与反方观点
Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2210-2. doi: 10.1158/1055-9965.EPI-06-1065.
8
Tamoxifen or raloxifene for breast cancer chemoprevention: a tale of two choices--point.他莫昔芬或雷洛昔芬用于乳腺癌化学预防：两种选择的故事——观点。
Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2207-9. doi: 10.1158/1055-9965.EPI-07-0629.
9
The current status of breast cancer chemoprevention: a star is born.乳腺癌化学预防的现状：一颗新星诞生了。
J Surg Oncol. 2007 Jan 1;95(1):4-5. doi: 10.1002/jso.20658.
10
Chemoprevention of breast cancer: a promising idea with an uncertain future.乳腺癌的化学预防：一个前景光明但未来不确定的想法。
Lancet. 2002 Sep 14;360(9336):813-4. doi: 10.1016/S0140-6736(02)11009-9.
引用本文的文献
1
First do no harm: extending the debate on the provision of preventive tamoxifen.首先，不要造成伤害：拓展关于提供预防性他莫昔芬的辩论。
Br J Cancer. 2001 Nov 2;85(9):1280-8. doi: 10.1054/bjoc.2001.2125.
2
Breast cancer prevention trials.乳腺癌预防试验。
Curr Oncol Rep. 2000 Nov;2(6):558-65. doi: 10.1007/s11912-000-0110-0.
3
Antiestrogens--tamoxifen, SERMs and beyond.抗雌激素药物——他莫昔芬、选择性雌激素受体调节剂及其他。
Invest New Drugs. 1999;17(3):285-311. doi: 10.1023/a:1006348907994.
4
Comprehensive pharmacology and clinical efficacy of aromatase inhibitors.芳香化酶抑制剂的全面药理学与临床疗效
Drugs. 1999 Aug;58(2):233-55. doi: 10.2165/00003495-199958020-00003.
5
Tamoxifen and breast cancer prevention: what should you tell your patients?他莫昔芬与乳腺癌预防：你该如何告知你的患者？
CMAJ. 1998 Jun 16;158(12):1615-7.
本文引用的文献
1
Breast cancer trial stopped early.乳腺癌试验提前终止。
BMJ. 1998 Apr 18;316(7139):1187. doi: 10.1136/bmj.316.7139.1185d.
2
Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women.BRCA1基因突变对阿什肯纳兹犹太女性乳腺癌核分级及雌激素受体状态的影响。
Cancer. 1997 Aug 1;80(3):435-41. doi: 10.1002/(sici)1097-0142(19970801)80:3<435::aid-cncr11>3.0.co;2-y.
3
Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.针对淋巴结阴性且雌激素受体阳性肿瘤的乳腺癌患者，他莫昔芬治疗五年与五年以上的对比。
J Natl Cancer Inst. 1996 Nov 6;88(21):1529-42. doi: 10.1093/jnci/88.21.1529.
4
Tamoxifen for the primary prevention of breast cancer: a review and critique of the concept and trial.他莫昔芬用于乳腺癌的一级预防：概念与试验的综述及评论
Epidemiol Rev. 1993;15(1):233-43. doi: 10.1093/oxfordjournals.epirev.a036110.
5
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.采用激素、细胞毒性或免疫疗法对早期乳腺癌进行全身治疗。133项随机试验，涉及75000名女性中的31000例复发和24000例死亡。早期乳腺癌试验协作组。
Lancet. 1992 Jan 4;339(8784):1-15.
Zotero 插件